Table 3.
TPE procedures performed according to clinical indications and reported complications
| Category (ASFA) | Patients | Median age, years | Male | Mean TPE sessions (SD) | Median Hct, % | Wt, kg | Median TPE volume, mL | Complications | Hypotension | Hypocalcaemia | Allergic reaction | CRBSI | |
| CNS disorders | |||||||||||||
| NMOSD (acute) | II | 28 (51%) | 39.9 (13–63) | 5 (18%) | 4.75 (0.8) | 36 (28–48) | 57 (36–111) | 2244 (1720–3455) | 11 (39%) | 6 (21%) | 3 (11%) | 0 (0%) | 3 (11%) |
| Acute CNS demyelinating disease (TM) | II | 8 (15%) | 33.5 (22–56.6) | 2 (25%) | 3.375 (1.8) | 35 (31–40) | 52 (42–80) | 2121 (1744–2943) | 4 (50%) | 1 (13%) | 2 (25%) | 0 (0%) | 1 (13%) |
| Multiple sclerosis | II | 3 (5%) | 38 (34–42) | 1 (33.3%) | 5 (0) | 40 (33–47) | 74 (65–79) | 2596 (2327–2912) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| CRION | N/A | 2 (4%) | 26.75 (26.5–27) | 2 (100%) | 5 (0) | 46 (43–47) | 62(62-64) | 2150 (2100–2199) | 2 (100%) | 2 (100%) | 0 (0%) | 0 (0%) | 0 (0%) |
| ADEM | II | 1 (2%) | 26 (—) | 1 (100%) | 1 (—) | 39 (—) | 64 (—) | 2517 (—) | 1 (100%) | 0 (0%) | 0 (0%) | 1 (100%) | 0 (0%) |
| NMDAR | I | 1 (2%) | 24 (—) | 0 (0%) | 5 (—) | 31 (29–34) | 45 (—) | 2100 (—) | 1 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (100%) |
| PNS and NMJ disorders | |||||||||||||
| GBS (AIDP) | I | 6 (11%) | 57 (19–60.5) | 3 (50%) | 4.25 (1.6) | 36 (3–44) | 51 (45–68) | 2273 (2047–2745) | 2 (33.3%) | 2 (33.3%) | 0 (0%) | 0 (0%) | 0 (0%) |
| CIDP | I | 2 (4%) | 32.75 (24–41.5) | 2 (100%) | 4.5 (0.7) | 44 (42–45) | 65.5 (60–71) | 2369 (2274–2463) | 1 (50%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (50%) |
| MG | I | 4 (7%) | 45.65 (45.3–46) | 0 (0%) | 5 (0) | 33 (30–40) | 54 (52–61) | 2270 (2000–2475) | 1 (25%) | 1 (25%) | 0 (0%) | 0 (0%) | 0 (0%) |
| All patients | 55 | 41 (13–63) | 16 (29%) | 4.5 | 36 (28–48) | 56 (36–111) | 2245 (1720–3455) | 23 (42%) | 12 (22%) | 5 (9%) | 1 (2%) | 6 (11%) | |
ADEM, acute disseminated encephalomyelitis; AIDP, acute inflammatory demyelinating polyneuropathy; ASFA, American Society for Apheresis; CIDP, chronic inflammatory demyelinating polyneuropathy; CNS, central nervous system; CRBSI, catheter-related blood stream infection; CRION, chronic relapsing inflammatory optic neuropathy; GBS, Guillain-Barre syndrome; Hct, haematocrit; MG, myasthenia gravis; NMDAR, N-methyl-D-aspartate receptor; NMJ, neuromuscular junction; NMOSD, neuromyelitis optica spectrum disorders; PNS, peripheral nervous system; TM, transverse myelitis; TPE, therapeutic plasma exchange.